All posts of Dr. Michael Chu

A Perspective on Immunotherapy Studies Presented at ASH 2018

In a continuation of the theme for ASH 2018, this summary is dedicated to immunotherapy. The next wave of chimeric antigen receptor (CAR) T cells is here, with a focus on next-generation designs or newer targets. Examples include dual-targeted CAR T cells aimed at CD19 and CD22 highlighted in the acute lymphoblastic leukemia (ALL) and […]

A Summary of Day 1 in Lymphoma from ASH 2018

Continuing the trend of the past 4–5 years, chimeric antigen receptor (CAR) T-cell studies are dominating the sessions so much so that organizers this year have split the abstracts into their own sessions. As opposed to updating clinical trial data, at ASH 2018, two groups of investigators looked into real-world evidence regarding the efficacy and […]

Summary of Day 3 – The Buzz About CAR T cells

In what was arguably the most attended lymphoma session at the meeting, Monday brought an update of many of the phase I/II chimeric antigen receptor (CAR) T-cell therapy studies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Updated results were presented from the JULIET (CTL019), ZUMA-1 (KTE C19), and TRANSCEND NHL 001 (JCAR017) studies, demonstrating […]

Summary of Day 2 – An Overview of Lymphoma Sessions

The second day of the ASH conference was highlighted by the plenary presentation by Canada’s very own Dr. Joe Connors, who presented the findings of ECHELON-1, a blinded, randomized phase III clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) vs. doxorubicin, vinblastine, and dacarbazine (AVD) plus brentuximab vedotin (BV) in advanced-stage classical Hodgkin’s lymphoma […]

Summary of Day 1 – Perspectives on Lymphoma Therapy

The annual ASH meeting brings together the global hematology community to review a variety of topics, from biology and pathophysiology to treatment and quality of life. Some of the most significant advances for lymphoma appear to be coming from the mantle cell lymphoma (MCL) studies. The number of compounds inhibiting Bruton’s tyrosine kinase (BTK) has […]
  • 1
  • 2